Nontuberculous Mycobacteria in Cystic Fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 39, Issue 3, 2018, Pages 383-391

  Furukawa, Brian S ^a   Flume, Patrick A ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

bronchiectasis; cavitary lung disease; cystic fibrosis; MAC; Mycobacterium abscessus; nontuberculous mycobacteria

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CYSTIC FIBROSIS; DISEASE TRANSMISSION; EPIDEMIOLOGY; HUMAN; LUNG DISEASE; LUNG TRANSPLANTATION; MASS SCREENING; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; COMPLICATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; SPUTUM; X-RAY COMPUTED TOMOGRAPHY;

CYSTIC FIBROSIS; HUMANS; LUNG TRANSPLANTATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RISK FACTORS; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85051195925     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0038-1651495     Document Type: Article

References (91)

1. Martiniano S. L. Sontag M. K. Daley C. L. Nick J. A. Sagel S. D. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc: 2014; 11 01 36 44
2. Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. 2017. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Annual-Data-Report.pdf. Accessed November 13, 2017
3. Goslee S. Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis: 1976; 113 03 287 292
4. Wolinsky E. Rynearson T. K. Mycobacteria in soil and their relation to disease-associated strains. Am Rev Respir Dis: 1968; 97 06 1032 1037
5. Gruft H. Falkinham J. O. III. Parker B. C. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis: 1981; 3 05 990 996
6. Falkinham J. O. III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis: 2011; 17 03 419 424
7. Cowman S. Burns K. Benson S. Wilson R. Loebinger M. R. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect: 2016; 72 03 324 331
8. Griffith D. E. Aksamit T. Brown-Elliott B. A., et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med: 2007; 175 04 367 416
9. Floto R. A. Olivier K. N. Saiman L., et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax: 2016; 71 01 i1 i22
10. Olivier K. N. Weber D. J. Wallace R. J. Jr., et al. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med: 2003; 167 06 828 834
11. Qvist T. Gilljam M. Jönsson B., et al. Scandinavian Cystic Fibrosis Study Consortium (SCFSC). Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros: 2015; 14 01 46 52
12. Pierre-Audigier C. Ferroni A. Sermet-Gaudelus I., et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol: 2005; 43 07 3467 3470
13. Fauroux B. Delaisi B. Clément A., et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J: 1997; 16 04 354 358
14. Whittier S. Hopfer R. L. Knowles M. R. Gilligan P. H. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol: 1993; 31 04 861 864
15. Jönsson B. E. Gilljam M. Lindblad A. Ridell M. Wold A. E. Welinder-Olsson C. Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol: 2007; 45 05 1497 1504
16. Bar-On O. Mussaffi H. Mei-Zahav M., et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros: 2015; 14 01 53 62
17. Olivier K. N. Weber D. J. Lee J. H., et al. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med: 2003; 167 06 835 840
18. Levy I. Grisaru-Soen G. Lerner-Geva L., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis: 2008; 14 03 378 384
19. Seddon P. Fidler K. Raman S., et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis: 2013; 19 07 1128 1130
20. Roux A. L. Catherinot E. Ripoll F., et al. Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol: 2009; 47 12 4124 4128
21. Campos-Herrero M. I. Chamizo F. J. Caminero J. A. Gilarranz R. Cabrera G. Cuyás J. Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study. J Infect Chemother: 2016; 22 08 526 531
22. Prevots D. R. Shaw P. A. Strickland D., et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med: 2010; 182 07 970 976
23. Adjemian J. Olivier K. N. Seitz A. E. Holland S. M. Prevots D. R. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med: 2012; 185 08 881 886
24. Sermet-Gaudelus I. Le Bourgeois M. Pierre-Audigier C., et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis: 2003; 9 12 1587 1591
25. Catherinot E. Roux A. L. Vibet M. A., et al. OMA group. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros: 2013; 12 01 74 80
26. Esther C. R. Jr. Esserman D. A. Gilligan P. Kerr A. Noone P. G. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros: 2010; 9 02 117 123
27. Binder A. M. Adjemian J. Olivier K. N. Prevots D. R. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med: 2013; 188 07 807 812
28. Bouso J. M. Burns J. J. Amin R. Livingston F. R. Elidemir O. Household proximity to water and nontuberculous mycobacteria in children with cystic fibrosis. Pediatr Pulmonol: 2017; 52 03 324 330
29. Catherinot E. Roux A. L. Vibet M. A., et al. OMA group. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J: 2013; 41 05 1101 1106
30. Coolen N. Morand P. Martin C., et al. Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. J Cyst Fibros: 2015; 14 05 594 599
31. Mussaffi H. Rivlin J. Shalit I. Ephros M. Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J: 2005; 25 02 324 328
32. Paugam A. Baixench M. T. Demazes-Dufeu N., et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol: 2010; 48 01 S32 S36
33. Viviani L. Harrison M. J. Zolin A. Haworth C. S. Floto R. A. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). J Cyst Fibros: 2016; 15 05 619 623
34. Knutsen A. P. Mueller K. R. Levine A. D. Chouhan B. Hutcheson P. S. Slavin R. G. Asp f I CD4+ TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol: 1994; 94 (2, Pt 1): 215 221
35. Skov M. Poulsen L. K. Koch C. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol: 1999; 27 02 74 79
36. Rodman D. M. Polis J. M. Heltshe S. L., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med: 2005; 171 06 621 626
37. Saiman L. Marshall B. C. Mayer-Hamblett N., et al. Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA: 2003; 290 13 1749 1756
38. Saiman L. Mayer-Hamblett N. Campbell P. Marshall B. C.; Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med: 2005; 172 08 1008 1012
39. Altenburg J. de Graaff C. S. Stienstra Y., et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA: 2013; 309 12 1251 1259
40. Wallace R. J. Jr. Brown-Elliott B. A. McNulty S., et al. Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest: 2014; 146 02 276 282
41. Renna M. Schaffner C. Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest: 2011; 121 09 3554 3563
42. Adjemian J. Olivier K. N. Seitz A. E. Falkinham J. O. III. Holland S. M. Prevots D. R. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med: 2012; 186 06 553 558
43. Adjemian J. Olivier K. N. Prevots D. R. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med: 2014; 190 05 581 586
44. Ziedalski T. M. Kao P. N. Henig N. R. Jacobs S. S. Ruoss S. J. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest: 2006; 130 04 995 1002
45. Kim R. D. Greenberg D. E. Ehrmantraut M. E., et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med: 2008; 178 10 1066 1074
46. Esther C. R. Jr. Henry M. M. Molina P. L. Leigh M. W. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol: 2005; 40 01 39 44
47. Griffith D. E. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med: 2003; 167 06 810 812
48. Sanguinetti M. Ardito F. Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol: 2001; 39 02 816 819
49. Verregghen M. Heijerman H. G. Reijers M. van Ingen J. van der Ent C. K. Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case-control study. J Cyst Fibros: 2012; 11 04 340 343
50. Qvist T. Taylor-Robinson D. Waldmann E., et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros: 2016; 15 03 380 385
51. Gilljam M. Berning S. E. Peloquin C. A. Strandvik B. Larsson L. O. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J: 1999; 14 02 347 351
52. van Ingen J. Egelund E. F. Levin A., et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med: 2012; 186 06 559 565
53. Koh W. J. Jeong B. H. Jeon K. Lee S. Y. Shin S. J. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med: 2012; 186 08 797 802
54. Hafner R. Bethel J. Power M., et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother: 1998; 42 03 631 639
55. Jarand J. Levin A. Zhang L. Huitt G. Mitchell J. D. Daley C. L. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis: 2011; 52 05 565 571
56. Koh W. J. Kim Y. H. Kwon O. J., et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci: 2008; 23 03 397 401
57. Ferro B. E. Meletiadis J. Wattenberg M., et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother: 2015; 60 02 1097 1105
58. Zuckerman J. M. Qamar F. Bono B. R. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am: 2011; 95 04 761 791, viii
59. Quon B. S. Goss C. H. Ramsey B. W. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc: 2014; 11 03 425 434
60. Colin A. A. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol: 2000; 30 03 267 268
61. Olivier K. N. Griffith D. E. Eagle G., et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med: 2017; 195 06 814 823
62. Olivier K. N. Shaw P. A. Glaser T. S., et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc: 2014; 11 01 30 35
63. Meers P. Neville M. Malinin V., et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother: 2008; 61 04 859 868
64. Rose S. J. Neville M. E. Gupta R. Bermudez L. E. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One: 2014; 9 09 e108703
65. Jeong B. H. Jeon K. Park H. Y., et al. Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother: 2016; 60 10 6076 6083
66. Jordan C. L. Noah T. L. Henry M. M. Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis. Pediatr Pulmonol: 2016; 51 (S44): S61 S70
67. Fohner A. E. McDonagh E. M. Clancy J. P. Whirl Carrillo M. Altman R. B. Klein T. E. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics: 2017; 27 01 39 42
68. Talamo Guevara M. McColley S. A. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf: 2017; 16 11 1305 1311
69. Maurer F. P. Castelberg C. Quiblier C. Böttger E. C. Somoskövi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother: 2014; 69 06 1559 1563
70. Kim H. Y. Kim B. J. Kook Y., et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol: 2010; 54 06 347 353
71. Choi G. E. Shin S. J. Won C. J., et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med: 2012; 186 09 917 925
72. Koh W. J. Jeon K. Lee N. Y., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med: 2011; 183 03 405 410
73. DaCosta A. Jordan C. L. Giddings O. Lin F. C. Gilligan P. Esther C. R. Jr. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. J Cyst Fibros: 2017; 16 04 483 487
74. Bange F. C. Brown B. A. Smaczny C. Wallace R. J. Jr. Böttger E. C. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis: 2001; 32 11 1648 1650
75. Aitken M. L. Limaye A. Pottinger P., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med: 2012; 185 02 231 232
76. Bryant J. M. Grogono D. M. Greaves D., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet: 2013; 381 (9877): 1551 1560
77. Bryant J. M. Grogono D. M. Rodriguez-Rincon D., et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science: 2016; 354 (6313): 751 757
78. Whitson B. A. Hayes D. Jr. Indications and outcomes in adult lung transplantation. J Thorac Dis: 2014; 6 08 1018 1023
79. Chalermskulrat W. Sood N. Neuringer I. P., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax: 2006; 61 06 507 513
80. Qvist T. Pressler T. Thomsen V. O. Skov M. Iversen M. Katzenstein T. L. Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transplant Proc: 2013; 45 01 342 345
81. Taylor J. L. Palmer S. M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant: 2006; 25 08 985 988
82. Chernenko S. M. Humar A. Hutcheon M., et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant: 2006; 25 12 1447 1455
83. Roux A. L. Catherinot E. Soismier N., et al. OMA group. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros: 2015; 14 01 63 69
84. Knoll B. M. Kappagoda S. Gill R. R., et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis: 2012; 14 05 452 460
85. Longworth S. A. Vinnard C. Lee I. Sims K. D. Barton T. D. Blumberg E. A. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis: 2014; 16 01 76 83
86. Lobo L. J. Noone P. G. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med: 2014; 2 01 73 82
87. Griffiths K. J. Experience of Mycobacterium abscessus eradication therapy at Aberdeen Royal Infirmary. J Cyst Fibros: 2015; 01 S126
88. Taccetti G. Campana S. Festini F. Mascherini M. Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J: 2005; 26 03 458 461
89. Qvist T. Pressler T. Taylor-Robinson D. Katzenstein T. L. Hoiby N. Serodiagnosis of Mycobacterium abscessus complex infection in cystic fibrosis. Eur Respir J: 2015; 46 03 707 716
90. Heslet L. Bay C. Nepper-Christensen S. The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm. J Inflamm Res: 2012; 5 19 27
91. Scott J. P. Ji Y. Kannan M. Wylam M. E. Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis. Eur Respir J: 2018; 51 04 pii